Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477566 | 1.00 | ACP3 (0.55) | ACP3MEN1KMT2ACNR2LMNA | |
| SCHEMBL424623 | 0.93 | ACP3 (0.50) | ACP3MEN1KMT2ALMNAADRB2 | |
| SCHEMBL11643856 | 0.91 | PTPN5 (0.48) | ACP3MEN1KMT2ACNR2ADRB3 | |
| SCHEMBL6002784 | 0.89 | ACP3 (0.44) | ACP3MEN1KMT2ACNR2LMNA | |
| SCHEMBL20788381 | 0.84 | ALDH1A1 (0.47) | ACP3MEN1KMT2ACNR2LMNA | |
| SCHEMBL14685882 | 0.84 | CYP19A1 (0.46) | ACP3MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL30529079 | 0.84 | ALDH1A1 (0.47) | ACP3MEN1KMT2ACNR2LMNA | |
| SCHEMBL6564479 | 0.84 | OPRM1 (0.46) | ACP3MEN1KMT2ATSHRSLC6A2 | |
| SCHEMBL30598700 | 0.84 | SMN1; SMN2 (0.52) | CNR2LMNATSHRSMN1; SMN2 | |
| SCHEMBL11605484 | 0.83 | ACP3 (0.55) | ACP3MEN1KMT2ALMNAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| CN-116082388-A | Method for preparing diphenyl dimethoxy silane from phenyl trimethoxy silane | 新亚强硅化学股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0706512-B1 | ACETAMIDE DERIVATIVES AND THEIR USE FOR MODIFYING FEEDING BEHAVIOUR MODIFIERS | LAFON LABOR (FR) | 1998-04-08 | — | — | EP | disclosed |
| US-5719168-A | Acetamide derivatives and their use as feeding behaviour modifiers | LABORATOIRE L. LAFON (FR) | 1998-02-17 | — | — | US | disclosed |
| EP-0801048-A1 | Process for producing benzhydrols | K I CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
| EP-0706512-A1 | ACETAMIDE DERIVATIVES AND THEIR USE FOR MODIFYING FEEDING BEHAVIOUR MODIFIERS | LABORATOIRE L. LAFON (FR) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001333-A1 | ACETAMIDE DERIVATIVES AND THEIR USE FOR MODIFYING FEEDING BEHAVIOUR MODIFIERS | LABORATOIRE L. LAFON (FR) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACP3 1293/4885MEN1 1855/4885KMT2A 1667/4885 |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACP3 1293/4885MEN1 1855/4885KMT2A 1667/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACP3 1293/4885MEN1 1855/4885KMT2A 1667/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACP3 1293/4885MEN1 1855/4885KMT2A 1667/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | ACP3 4339/4885MEN1 2625/4885KMT2A 843/4885 |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | ACP3 4636/4885MEN1 4143/4885KMT2A 3137/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACP3 1293/4885MEN1 1855/4885KMT2A 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.